These results suggest that while TLR9 agonist has been shown to induce both Th1 and Th2 immune response, single fraction 20 Gy to the tumor might shape the immune response toward a Th2-bias, which facilitates the generation of tumor-reactive antibodies. Here, TLR9 is linked to neoplasm.